Criterium's Academic Breast Cancer Consortium (ABRCC) is comprised of 15 renowned academic and community sites in North America, conducting translational research in Breast Cancer studies for major pharmaceutical companies who are working on the most current clinical trials for advanced treatments of breast cancer. While 2020 was a year dominated by COVID-19 news and tragedy, breast cancer research and breakthroughs can't wait for COVID to "go away" – and research in this area continues on full-speed. Our ABRCC researchers reflect on 2020 and look ahead to 2021 with renewed hope.
News & Blog
GET TO KNOW US!
AllAllergyAsthmaBest PracticesCase StudiesClinical ResearchCNS/NeurologyConsortiaCriterium NewsData ManagementDermatologyEDCFDAGastroenterologyGlobal Clinical ResearchHematologyIndustry NewsInfectious DiseaseIVR-IWR IxRSMedical DevicesMen's HealthMetabolic SyndromeOncologyOphthalmologyOrphan DiseasesOutsourcingPain ManagementPharmaceutical DevelopmentPress ReleasesPublic InterestTranslational ResearchTrial TechnologyUrologyWomen's Health
For November's Lung Cancer Awareness Month, Heather Smith and Melissa Turner share the stories of their cancer journeys. The women took very different routes to the CU Cancer Center and the world-renowned lung cancer care of Ross Camidge, MD. On this episode of the CU Anschutz 360 podcast, learn why they love everything about Dr. Camidge’s practice, especially the fact that he makes them laugh.
Findings from a CHOP/Penn Medicine study could lead to treatment for patients with lung disease, including acute respiratory distress syndrome due to COVID-19.
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Preliminary results from phase 1 clinical trial of WP1220 for treatment of
Research from the O’Neal Comprehensive Cancer Center at UAB finds patients treated outside of NCCN Guidelines recommendations had significantly higher direct costs. A new study from the O’Neal Comprehensive Cancer
The U.S. Food and Drug Administration is warning consumers not to purchase or use drugs advertised nationwide as a “healthy man alternative to the little blue pill” or “healthy man,”
- What’s New in Breast Cancer Research and Treatment?
- Podcast: ‘You Have to Personalize the Miracles’
- Researchers Identify “Druggable” Signaling Pathway that Stimulates Lung Tissue Repair
- Positive Trial Data with 100% Safe Delivery
- Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients